✦ LIBER ✦

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression

✍ Scribed by Reguart, Noemi; Rosell, Rafael; Cardenal, Felipe; Cardona, Andres F.; Isla, Dolores; Palmero, Ramon; Moran, Teresa; Rolfo, Christian; Pallarès, M. Cinta; Insa, Amelia; Carcereny, Enric; Majem, Margarita; De Castro, Javier; Queralt, Cristina; Molina, Miguel A.; Taron, Miquel

Book ID: 122295522
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 645 KB
Volume: 84
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2014.02.011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

9150 Phase I trial of vorinostat in comb

9150 Phase I trial of vorinostat in combination with erlotinib for advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations after erlotinib progression (NCT00503971): The TARZO trial

✍ Reguart, N.; Isla, D.; Cardona, A.F.; Palmero, R.; Cardenal, F.; Rolfo, C.; Mont 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

9141 POSTER Phase l/ll Trial of Vorinost

9141 POSTER Phase l/ll Trial of Vorinostat (V) in Combination With Erlotinib (E) in Advanced Non-small Cell Lung Cancer (NSCLC) Patients (pts) With EGFR Mutations After Erlotinib Progression – the TARZO Trial (NCT00503971)

✍ Cardenal, F.; Reguart, N.; Morán, T.; Insa, A.; Isla, L.; Magern, M.; Rolfo, C.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Erlotinib as first-line treatment of Eur

Erlotinib as first-line treatment of European non-small-cell lung cancer (NSCLC) patients (pts.) with epidermal growth factor receptor (EGFR) activating mutations (mut+)

✍ Petruzelka, Lubos 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Phase II trial of erlotinib in patients

Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics

✍ Motoshima, Kohei; Nakamura, Yoichi; Sano, Kazumi; Ikegami, Yoji; Ikeda, Takaya; 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 227 KB

9016 POSTER DISCUSSION Erlotinib Vs Chem

9016 POSTER DISCUSSION Erlotinib Vs Chemotherapy (CT) in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients (p) With Epidermal Growth Factor Receptor (EGFR) Activating Mutations – the EURTAC Phase II Randomized Trial Interim Results

✍ De Marinis, F.; Rosell, R.; Vergnenegre, A.; Massuti, B.; Felip, E.; Gervais, R. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB

A prospective, phase II, open-label stud

A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)

✍ Goto, Koichi; Nishio, Makoto; Yamamoto, Noboru; Chikamori, Kenichi; Hida, Toyoak 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 948 KB